Evidence map›Paper›PMID 38988509›Full record

ArticleHeliyon2024

Atrial fibrillation recurrence after catheter ablation is associated with RAD51 and p63 proteins.

Nadezhda G Gumanova, Polina D Zlobina, Natalya L Bogdanova, Hakob A Brutyan, Elena N Kalemberg, Ya I Havrichenko, Karapet V Davtyan, Oxana M Drapkina

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05170607 (Investigation of Specific Biomarkers in Patients With Atrial Fibrillation Who Undergo Interventional Treatment), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05170607 active not recruitingnot on this map

Investigation of Specific Biomarkers in Patients With Atrial Fibrillation Who Undergo Interventional Treatment

TypeobservationalSponsorNational Medical Research Center for Therapy and Preventive MedicineRan2021 to 2028Enrolled120ConditionsAtrial FibrillationArmsProteomic analysis by antibody microarrays
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nadezhda G GumanovaDepartment of Biochemistry, National Research Center for Preventive Medicine (NRCPM), Moscow, Russia.
Polina D ZlobinaCardiac Arrhythmia Department, National Research Center for Preventive Medicine, 10 Petroverigsky per., Building 3, Moscow, 101990, Russia.
Natalya L BogdanovaDepartment of Biochemistry, National Research Center for Preventive Medicine (NRCPM), Moscow, Russia.
Hakob A BrutyanCardiac Arrhythmia Department, National Research Center for Preventive Medicine, 10 Petroverigsky per., Building 3, Moscow, 101990, Russia.
Elena N KalembergCardiac Arrhythmia Department, National Research Center for Preventive Medicine, 10 Petroverigsky per., Building 3, Moscow, 101990, Russia.
Ya I HavrichenkoDepartment of Biochemistry, National Research Center for Preventive Medicine (NRCPM), Moscow, Russia.
Karapet V DavtyanCardiac Arrhythmia Department, National Research Center for Preventive Medicine, 10 Petroverigsky per., Building 3, Moscow, 101990, Russia.
Oxana M DrapkinaNational Research Center for Preventive Medicine, 10 Petroverigsky per., Building 3, Moscow, 101990, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Catheter ablation has been demonstrated to reduce atrial fibrillation (AF) recurrence. The mechanisms of AF recurrence after catheter ablation are unknown, and the present study aimed to identify serum proteins associated with AF recurrence. The present prospective study comprised a cohort of patients with AF, which was divided into two groups after one-year follow-up: group 1 included patients with compensated AF after catheter ablation and group 2 included patients with AF recurrence after catheter ablation. Initial microarray profiling of the serum proteins was performed in small subgroups M1 and M2 recruited from groups 1 and 2, respectively, by an antibody microarray to evaluate potentially relevant proteins. The data of initial proteomic profiling identified candidate proteins in groups 1 and 2, and their levels were then measured by ELISA. The data of profiling suggested an overall increase in the levels of RAD51 and p63 proteins in the M2 subgroup versus that in the M1 subgroup, indicating potential relevance of these two proteins to AF recurrence. The results of ELISA of the levels of RAD51 and p63 in the groups 1 and 2 demonstrated an increase in the levels of RAD51 (11.11 ± 4.36 vs 8.45 ± 4.85 ng/mL; P = 0.009) and p63 (165.73 ± 113.75 vs 100.05 ± 37.56 units of normalized optical density; P = 0.0007) in the group 2 (with AF recurrence or substrate AF) compared with that in the group 1 (compensated AF). Thus, RAD51 and p63 were associated with AF recurrence after catheter ablation and may represent possible etiological factors for subsequent outcomes.

Indexed as

Antibody microarrayAtrial fibrillation recurrenceCatheter ablationp63 proteinRAD51 protein

Identifiers

PMID38988509
PMCPMC11233995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.